Dr. Lalezari stated, “I am honored to accept the

Dr. Lalezari stated, “I am honored to accept the position of CEO during this crucial transition period for CytoDyn. Our clinical protocol in HIV+ subjects with immune activation has been revised per FDA guidance and, assuming the removal of the current hold on the trial protocol, we hope to initiate the trial this year."

I don't think he would have been made permanent CEO or have mentioned the protocol, if there had not been some assurance from the FDA.